Century Therapeutics (NASDAQ:IPSC) vs. Invizyne Technologies (NASDAQ:IZTC) Financial Survey

Century Therapeutics (NASDAQ:IPSC) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, dividends, analyst recommendations and profitability.

Valuation and Earnings

This table compares Century Therapeutics and Invizyne Technologies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$6.59 million	6.50	-$136.67 million	($1.63)	-0.31
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Invizyne Technologies has lower revenue, but higher earnings than Century Therapeutics.

Insider & Institutional Ownership

50.2% of Century Therapeutics shares are owned by institutional investors. 6.8% of Century Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Century Therapeutics and Invizyne Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	-4,837.73%	-61.66%	-31.78%
Invizyne Technologies	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current recommendations for Century Therapeutics and Invizyne Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	0	0	5	0	3.00
Invizyne Technologies	0	0	0	0	0.00

Century Therapeutics presently has a consensus target price of $4.40, indicating a potential upside of 784.24%. Given Century Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Century Therapeutics is more favorable than Invizyne Technologies.

Summary

Century Therapeutics beats Invizyne Technologies on 6 of the 9 factors compared between the two stocks.

About Century Therapeutics

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

About Invizyne Technologies

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.